Thursday, 9 May 2024
  
Login

Australia's most trusted
source of pharma news

Thursday, 09 May 2024
Listen to this story 
News

CEO pay plummets 87%

Posted 26 April 2024 PM

In what's likely to be the biggest comedown in CEO salaries reported this year, Biogen's Chris Viehbacher saw his remuneration package drop through the floor - by 87 per cent - but it had nothing to do with his performance.

The drop was expected given he received bumper financial incentives as part of a sign-on package when he took up the Biogen top job in November 2022. That year he was paid AU$45 million (US$30.6 million) for two months' work. But part of the deal meant Viehbacher didn't receive any stock or option awards for 2023.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (5)

Sales & Customer Relations (23)

Clinical & Medical, R&D (11)

Regulatory, Pharmacovigilance & QA (10)

Other (30)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.